Snowden Capital Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Snowden Capital Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-4,865	Closed	-$388K	–	1184
2022 Q2	$388K	Buy	4,865 +76	+2%	+$7.2K	0.02%	750
2022 Q1	$503K	Buy	4,789 +4,719	+6,741%	+$460K	0.02%	629
2021 Q4	$7K	Sell	70 -4,523	-98%	-$493K	﹤0.01%	1632
2021 Q3	$503K	Buy	+4,593	New	+$477K	0.03%	536

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Snowden Capital Advisors's HZNP Position: Q3 2022 in Review

Snowden Capital Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2022, closing a stake of 4,865 shares — an estimated $388K sold.

Snowden Capital Advisors first reported a position in HZNP in Q3 2021 and held it in 4 quarters. The position peaked at $503K in Q3 2021. 530 funds tracked by Wall St. Rank hold HZNP as of Q3 2022.

Snowden Capital Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2022 after selling out during the quarter.
Snowden Capital Advisors sold 4,865 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2022, an estimated $388K.
Snowden Capital Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2021 and held it in 4 quarters.
Snowden Capital Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $503K in Q3 2021.
530 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2022.

Based on Snowden Capital Advisors's 13F filing for Q3 2022, filed 9 Nov 2022.